Background The use of immune checkpoint inhibitors (ICIs) has become standard therapy in
many tumor sites. The aim of this study is to systematically review the literature to determine …

Background A number of studies have reported an association between the occurrence of
immune-related adverse events (irAEs) and clinical efficacy in patients undergoing treatment …

Background Immune-related adverse events (irAEs) are frequently reported during immune
checkpoint inhibitor (ICI) therapy and are associated with long-term outcomes. It is unknown …

Immune-related adverse events (irAEs) are autoimmune-toxic effects associated with
immune checkpoint inhibitors (ICIs) used for the treatment of advanced solid tumors. We …

Background Targeting immune checkpoints is a novel approach in cancer therapy. This
strategy may trigger immune related adverse events (irAE). We hypothesize that the …

The advent of immune checkpoint‐inhibitors (CPI) has transformed treatment for several
cancer types. This review was performed to assess the rate of adverse events (AEs) …

Objectives Immune checkpoint inhibitors (ICIs) have brought impressive benefits to cancer
patients, however often accompanied with immune-related adverse events (irAEs). We …

Purpose This study was designed to investigate the correlation between immune-related
adverse events (irAEs) of immune checkpoint inhibitors (ICIs) and corresponding efficacy …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Background: Although clinical practice guidelines for the management of Immune
Checkpoint Inhibitor (ICI)-related adverse events have recently been published, precise and …